A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

550 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-13

Study Completion Date

2030-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year period

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris

NCT01595997

Mild-to-moderate Psoriasis Vulgaris

COMPLETED PHASE1/PHASE2

A Study of Deucravacitinib to Treat LPP and FFA

NCT06091956

Lichen Planopilaris

COMPLETED PHASE2

Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients

NCT01936337

Psoriasis Vulgaris

COMPLETED PHASE2

Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

NCT02969018

Chronic Plaque Psoriasis

COMPLETED PHASE2

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

NCT06382987

Plaque Psoriasis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plaque Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Moderate-to-severe plaque psoriasis

Deucravacitinib

Intervention Type DRUG

Non-interventional observational study of patients receiving treatment with commercially available deucravacitinib 6 mg once daily according to the Summary of Product Characteristics

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deucravacitinib

Non-interventional observational study of patients receiving treatment with commercially available deucravacitinib 6 mg once daily according to the Summary of Product Characteristics

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a physician-reported diagnosis of moderate-to-severe plaque psoriasis initiating deucravacitinib according to approved label in the European Union
* The decision upon treatment with deucravacitinib must have been made before enrollment and independently of this non-interventional observational study
* Patient is at least 18 years of age at the time of treatment decision
* Patient provided written informed consent to participate in the study

Exclusion Criteria

* Any contraindications according to the approved deucravacitinib Summary of Product Characteristics
* Prior treatment with deucravacitinib
* Simultaneous participation in an interventional clinical trial for moderate-to-severe psoriasis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No